Recruiting

CD34+ Stem Cell

Sponsor:

NYU Langone Health

Code:

NCT06569082

Conditions

Graft Failure

Poor Graft Function

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CD34+ Selected Donor Cell Boost

Blood Stem Cell Infusion

Study Details

Brief summary:

The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.

Conditions

Graft Failure

Poor Graft Function

Study ID

NCT06569082

Start date

Oct 31, 2024

Status verified date

Aug, 2026

Completion date

Aug, 2035

Anticipated

Primary completion date

Aug, 2034

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Recipient of allogeneic transplantation, adult ≥18 years, from any type of donor including matched related, matched unrelated, mismatched related or mismatched unrelated or haploidentical donor transplant.
  • Documented evidence of graft dysfunction or failure (a-c):

1. Primary graft Failure: Graft failure is defined as failure to achieve neutrophil engraftment by day +28 or lack of donor chimerism > 50% by day 45 not due to the underlying malignancy;
2. Poor graft function is defined by at least 2 of the following 3 criteria: Hemoglobin < 8 g/dL, ANC < 0.5x109/L, and platelets < 20x109/L. The cytopenia must be unexplained (such as by disease relapse) and unresponsive to hematopoietic growth factors and must last at least 4 weeks;
3. Secondary graft failure is defined as poor graft function associated with donor chimerism < 5% after initial engraftment
  • Transplanted donor availability
  • Negative pregnancy test within seven (7) days of product infusion for women of childbearing potential.

Exclusion Criteria:

  • Graft failure due to disease relapse or evidence of disease relapse or progression
  • Donor unavailable or unable to collect peripheral HPC by apheresis
  • Responsive to conventional measures (such as, hematopoietic growth factor)
  • Allergic reaction to murine proteins or iron dextran
  • Women of childbearing potential with positive serum HCG

Study Design

Enrollment

21 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Individuals with Poor Graft Function or Failure Following Allogeneic HSCT

The recipient will undergo evaluations, then undergo a single infusion of CD34 selected HSCT from the original donor.

No additional GvHD prophylaxis will be administered. Patients who develop GvHD will receive the standard of care based on the discretion of the treating physician .

Patients will receive supportive care per institutional standards and at the discretion of the treating physician.

Interventions

CD34+ Selected Donor Cell Boost

The CliniMACS CD34 Reagent System is used to separate CD34 cells from the remaining stem cell product, using a peripheral blood stem cell sample provided by the original donor. These CD34 cells are then infused into the recipient following selection with the intent to restore function of the blood forming cells.

Blood Stem Cell Infusion

The selected CD34 cells separated by the CliniMACS CD34 Reagent System are infused into the recipient.

Primary outcome measure

  • Number of Participants with Absolute Neutrophil Cell (ANC) Engraftment [ Time Frame: Day 100 Post-Procedure ]
  • Number of Participants with Platelet Engraftment [ Time Frame: Day 100 Post-Procedure ]

Central Contacts and Locations

Locations

NYU Langone Health

Recruiting

New York, New York, United States, 10016

More Information

Sponsor

NYU Langone Health

Last update posted

Aug 17, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by NYU Langone Health on 2026-08-17.